ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

Key Takeaway: ImmunityBio is set to present new comparative data and scientific advancements related to non-muscle invasive bladder cancer at the upcoming American Urological Association Annual Meeting. The presentation will also include an update on their BCG Naïve Registrational Trial. This event is expected to highlight the company's contributions to bladder cancer research.